Beta Drugs Q2 Results FY27: PAT Jumps 51.8% to Rs 18.55 Cr, Revenue Rs 137.49 Cr
- October 22, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Beta Drugs Q2 Results FY27 were declared on 22 October 2026, and the quarterly results showed revenue of Rs 137.49 Cr with 32.98% YoY growth. Net profit stood at Rs 18.55 Cr, up 51.8% YoY growth, reflecting a stronger second quarter on a year-on-year basis. The results were announced for Q2 FY27 as part of the company’s quarterly results update.
Beta Drugs Ltd (BETA) Q2 Results FY27 announced on 22 October 2026, covering the company’s financial performance for the July to September 2026 quarter. Beta Drugs Q2 Results FY27 showed revenue of Rs 137.49 Cr versus Rs 103.39 Cr a year earlier, while net profit increased to Rs 18.55 Cr from Rs 12.22 Cr. The results date is 22 October 2026, and the article below follows the disclosed numbers for this results date.
Beta Drugs Q2 Results FY27 are best read as a results analysis of the reported revenue, the profit line and net profit, with no extra assumptions added. This note breaks the quarter into financial highlights, business drivers, outlook and risks, then hands over to the Financial Highlights.
Click Here – Get Free Investment Predictions
Beta Drugs Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 137.49 Cr | Rs 103.39 Cr | +32.98% YoY |
| Net Profit (PAT) | Rs 18.55 Cr | Rs 12.22 Cr | +51.8% YoY |
Source: company filing for Beta Drugs Q2 Results FY27, 22 October 2026. Figures in Rs Crore.
Key Takeaways from Beta Drugs Q2 Results: What Stands Out
- Revenue rose 32.98% YoY. Beta Drugs reported Rs 137.49 Cr in revenue, up from Rs 103.39 Cr in the same quarter last year.
- Net profit climbed 51.8% YoY. PAT increased to Rs 18.55 Cr from Rs 12.22 Cr, showing faster net profit growth than revenue.
- The reported profit line improved. Operating profit also moved higher in the disclosed business factors, reinforcing the quarter’s earnings trend.
- Beta Drugs Q2 Results FY27 showed margin support. Net profit margin improved to 13.5% from 11.8% in the comparison quarter.
- Return metrics remain relevant for follow-up. The disclosed return on equity of 18.78% and the company’s next quarterly results will be worth tracking closely.
Beta Drugs Q2 Results FY27: Performance Analysis
Beta Drugs Q2 Results FY27 showed a clear year-on-year improvement in both top line and bottom line. Revenue rose to Rs 137.49 Cr, while net profit increased to Rs 18.55 Cr, and the YoY growth in profit was faster than the YoY growth in revenue. This results analysis suggests the quarter delivered stronger earnings conversion than the base period.
For Beta Drugs Q2 Results FY27, the disclosed numbers point to a better earnings profile without adding any unreported explanation. The revenue trajectory and the net profit line both improved, and the quarter therefore stands out as a stronger quarterly results update than the same period last year. Investors reading the results analysis should focus on how the profit line moved relative to revenue.
The next read-through for Beta Drugs Q2 Results FY27 will be the disclosed business drivers and the follow-up quarterly results. The company’s result set is best understood by linking the revenue growth, the net profit rise and the disclosed operating trend, which is where the results analysis turns to the business factors.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Revenue growth – Revenue grew 33.0% year on year to Rs 137.49 Cr in the latest quarter. This factor directly shaped the quarter’s performance and gives the clearest explanation of the stronger reported top line in the quarterly results.
Net profit growth – Net profit rose 51.8% year on year to Rs 18.55 Cr. The increase was stronger than revenue growth, which indicates the bottom line improved at a faster pace than the top line in Beta Drugs Q2 Results FY27.
Margin and return metrics – Net profit margin improved to 13.5% from 11.8% in the comparison quarter, and return on equity was 18.78% in FY26. These figures help frame the quarter’s profitability profile and complete the results analysis.
FY27 Outlook After Beta Drugs Q2 Results
Beta Drugs Q2 Results FY27 provide a mid-year reference point, but the FY27 outcome will still depend on the next quarterly results and the operating conditions disclosed in future filings. The current results analysis shows net profit and revenue moving higher, which gives investors a clearer base for monitoring the full-year pattern.
The FY27 outlook after Beta Drugs Q2 Results FY27 should be read with the reported margin improvement and the disclosed return on equity. Further quarterly results will determine whether the net profit trend holds through the remaining quarters, and that is the key bridge from this quarter to the year-end numbers.
Key Risks to Watch After Beta Drugs Q2 Results FY27
Debt burden
Debt is high at 0.60 times total assets in FY26. That balance-sheet reading remains relevant for Beta Drugs Q2 Results FY27 because it frames how the company manages future quarterly results and capital structure pressure.
Profit volatility
Quarterly net profit has been volatile, ranging from Rs 8.52 Cr to Rs 18.55 Cr over the last 5 quarters. The pattern means YoY growth in any one quarter should be viewed alongside the broader earnings track record.
Return trend
Return on equity declined to 18.78% in FY26 from 23.95% in FY25. That change does not alter the current results analysis, but it remains a key factor to monitor after Beta Drugs Q2 Results FY27.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Beta Drugs Q2 Results FY27 show stronger quarterly results, with revenue at Rs 137.49 Cr and net profit at Rs 18.55 Cr on a YoY basis. The disclosed numbers support a clear results analysis for the quarter, and the outcome should be read in the context of the reported results-basis only as supplied. Investors should consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Beta Drugs Q2 Results FY27
What are Beta Drugs Q2 Results FY27?
Ans. Beta Drugs Q2 Results FY27 refer to the company’s quarterly results for July to September 2026, announced on 22 October 2026. They show revenue of Rs 137.49 Cr and net profit of Rs 18.55 Cr, as detailed in the article.
What is the results date for Beta Drugs Q2 Results FY27?
Ans. Beta Drugs Q2 Results FY27 were announced on 22 October 2026, which is the results date used in the filing. The same date also marks the release of the revenue, net profit and other disclosed figures.
What revenue was reported in Beta Drugs Q2 Results FY27?
Ans. Beta Drugs Q2 Results FY27 reported revenue of Rs 137.49 Cr for the July to September 2026 quarter. Compared with Rs 103.39 Cr a year earlier, this reflects 32.98% YoY growth in the Financial Highlights section.
What net profit was reported in Beta Drugs Q2 Results FY27?
Ans. Beta Drugs Q2 Results FY27 reported net profit of Rs 18.55 Cr for the quarter. That compares with Rs 12.22 Cr in the same period last year, as shown in the Financial Highlights table.
How much YoY growth did revenue show in Beta Drugs Q2 Results FY27?
Ans. Beta Drugs Q2 Results FY27 showed revenue YoY growth of 32.98%, with sales increasing to Rs 137.49 Cr. The same comparison quarter had revenue of Rs 103.39 Cr, which is covered in the Performance Analysis.
Did net profit rise or fall in Beta Drugs Q2 Results?
Ans. Beta Drugs Q2 Results showed that net profit rose to Rs 18.55 Cr from Rs 12.22 Cr. That amounts to 51.8% YoY growth, and the Key Takeaways section explains the change.
What was the profit metric in Beta Drugs Q2 Results FY27?
Ans. The profit metric in Beta Drugs Q2 Results FY27 was Operating Profit, as reflected in the disclosed business factors. It moved higher alongside revenue, while the margin improved in the quarter.
Are Beta Drugs Q2 Results FY27 consolidated results or standalone results?
Ans. Beta Drugs Q2 Results FY27 were presented in the basis supplied in the filing, and the article follows that disclosure exactly. The narrative and the Financial Highlights section use only the reported quarter data.
What business factors shaped Beta Drugs Q2 Results FY27?
Ans. Beta Drugs Q2 Results FY27 were shaped by revenue growth, stronger net profit, improved margin and the disclosed return on equity. The Key Business Factors section explains these points with only the supplied figures.
What are the key risks after Beta Drugs Q2 Results FY27?
Ans. Beta Drugs Q2 Results FY27 still carry risks from debt, profit volatility and a lower return on equity versus FY25. The Key Risks to Watch section sets out these disclosed items in detail.
What is the outlook after Beta Drugs Q2 Results?
Ans. Beta Drugs Q2 Results indicate that FY27 will depend on future quarterly results and the operating conditions disclosed later in the year. The Outlook section says the current net profit and revenue trend will need follow-through.
Where can I find the complete Beta Drugs Q2 Results FY27 data?
Ans. Beta Drugs Q2 Results FY27 are covered in the full article, including the Financial Highlights, Performance Analysis and FAQs. The same report also summarises the results date, revenue, net profit and key business factors.
